On December 6, 2018, at 08:00 am CET, Biovica International AB (publ) will publish its interim report for the second quarter 2018. All interested parties are invited to participate in a web-cast telephone conference, which will include a presentation, on the same day at 09:00 am CET. The event will be hosted by Biovica’s CEO Anders Rylander and CFO Cecilia Driving. The presentation will be held in English.
How to participate:
The live webcast and a recorded on-demand version including the presentation material will be accessible at:
Questions can be asked in writing via the webcast or verbally via the conference call.
To participate in the conference call, please call one of the following numbers:
The presentation material will also be published on Biovica’s website http://biovica.com/investor-relations/presentationer/. The webcast, and later the recorded version of the webcast and the conference call, will also be accessible via Sedana Medical’s website.
Anders Rylander, CEO Biovica.
Phone: +46 (0)18 444 48 35,
Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.
Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB.
Read more: www.biovica.com